Comprehensive Genomic Profiling (CGP) expands precision medicine’s utility
With the first TKI therapy Imatinib (Gleevec) targeting the fusion BCR-ABL1, approved by FDA in 2001, we have witnessed the birth of modern targeted therapy and personalized medicine.
Diagnostic Symposium
Join NeoGenomics for our upcoming Diagnostic Symposium on Tuesday, May 10, 9 to 10 a.m. PT.
Travelogue 2
On Saturday, March the 12th, after 28 days in China, I was finally allowed to travel to Suzhou.
Travelogue 1
My life as a volunteer prisoner ended on Friday the 4th of March. I have to admit that it has been a pretty gloomy three weeks.
Talking Cancer: Conversation with Ultramarathoner, Triathlete, Mother, Wife, Business Owner and Overachiever, Isabella de la Houssaye
To say Isabella de la Houssaye is an overachiever, would be minimizing what she is—a triathlete, a climber, a marathoner, a long-distance runner, a mother, wife and business owner, she epitomizes a
Using Real-World Lab Data Insights to Improve Biomarker Testing in Lung Cancer
As a medical community, our understanding of the lung cancer universe has become increasingly sophisticated in recent years and as a result, significant advancements have been seen in targeted ther
First CDx Approval for HLA Typing
We have seen HLA typing become more prominent in oncology clinical studies. Especially in the realm of immuno-oncology therapeutics including CAR T-cells, bi-specifics, and cancer vaccines.
Talking Cancer Blog: A Conversation with Holly Smithson, Athena CEO & Diversity Champion